HT-0712 is under clinical development by Dart NeuroScience and currently in Phase II for Age Related Memory Impairment. According to GlobalData, Phase II drugs for Age Related Memory Impairment does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the HT-0712 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

HT-0712 overview

HT-0712 is under development for the treatment of age-associated memory impairment. It is administered orally as a capsule. The drug candidate is a small molecule, it acts by targeting phosphodiesterase 4 (PDE4).

Dart NeuroScience overview

Dart NeuroScience is a specialized pharmaceutical company. The company provides genetic, biochemical, physiological, and behavioral techniques to identify genes, networks, and pathways underlying cognitive processes; and drug screening and medicinal chemistry to develop compounds for treating cognitive and motor disorders and enhancing brain functions. It provides chemical, structural, and computational procedures to chemical libraries and design new molecules that interact with proteins in the CNS; assays and diagnostics to analyze functional properties in specific brain domains; and specialized therapies to rehabilitate and enhance brain function. The company also provides drug development programs such as PDE4 program, MAO-B program, GlyT1 program, GABA-A program and novel programs. Dart NeuroScience is headquartered in San Diego, California, the US.

For a complete picture of HT-0712’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.